Yusuke Yamamoto

Dr. Yusuke Yamamoto

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TITaisuke Imamura
Taisuke Imamura
YYYusuke Yamamoto
Yusuke Yamamoto
TSTeiichi Sugiura
Teiichi Sugiura
YOYukiyasu Okamura
Yukiyasu Okamura
TITakaaki Ito
Takaaki Ito
KUKatsuhiko Uesaka
Katsuhiko Uesaka

1 November 2014 in Pancreatology
Verified
Journal Article
Closed access
YYYusuke Yamamoto
Yusuke Yamamoto
HIHisashi Ikoma
Hisashi Ikoma
RMRyo Morimura
Ryo Morimura
HKHirotaka Konishi
Hirotaka Konishi
YMYasutoshi Murayama
Yasutoshi Murayama
EOEigo Otsuji
Eigo Otsuji

21 February 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TITaisuke Imamura
Taisuke Imamura
YYYusuke Yamamoto
Yusuke Yamamoto
TSTeiichi Sugiura
Teiichi Sugiura
YOYukiyasu Okamura
Yukiyasu Okamura
TITakaaki Ito
Takaaki Ito
KUKatsuhiko Uesaka
Katsuhiko Uesaka

1 July 2021 in BJS Open
Verified
Journal Article
Open access
PDF file
TST Sugiura
T Sugiura
KUK Uesaka
K Uesaka
YOY Okamura
Y Okamura
TIT Ito
T Ito
YYYusuke Yamamoto
Yusuke Yamamoto
KAK Asakura
K Asakura
Hepatectomy with vascular resection (VR) for perihilar cholangiocarcinoma (PHCC) is a challenging procedure. However, only a few reports on this procedure have been published and its clinical significance has not been fully evaluated. Patients undergoing surgical resection for PHCC from 2002–2017 were studied. The surgical outcomes of VR and non-VR groups were compared. Some 238 patients were included. VR was performed in 85 patients. The resected vessels were hepatic artery alone (31 patients), portal vein alone (37 patients) or both (17 patients). The morbidity rates were almost the same in the VR (49.4 per cent) and non-VR (43.8 per cent) groups (P = 0.404). The mortality rates of VR (3.5 per cent) and non-VR (3.3 per cent) were also comparable (P > 0.999). The median survival time (MST) was 45 months in the non-VR group and 36 months in VR group (P = 0.124). Among patients in whom tumour involvement was suspected on preoperative imaging and whose carbohydrate antigen 19-9 (CA19-9) value was 37 U/ml or less, MST in the VR group was significantly longer than that in the non-VR group (50 versus 34 months, P = 0.017). In contrast, when the CA19-9 value was greater than 37 U/ml, MST of the VR and non-VR groups was comparable (28 versus 29 months, P = 0.520). Hepatectomy with VR for PHCC can be performed in a highly specialized hepatobiliary centre with equivalent short- and long-term outcomes to hepatectomy without VR.

26 June 2019 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
KOKatsuhisa Ohgi
Katsuhisa Ohgi
TSTeiichi Sugiura
Teiichi Sugiura
YYYusuke Yamamoto
Yusuke Yamamoto
YOYukiyasu Okamura
Yukiyasu Okamura
TITakaaki Ito
Takaaki Ito
KUKatsuhiko Uesaka
Katsuhiko Uesaka

1 March 2016 in Surgery
Verified
Journal Article
Closed access
YYYusuke Yamamoto
Yusuke Yamamoto
TSTeiichi Sugiura
Teiichi Sugiura
YOYukiyasu Okamura
Yukiyasu Okamura
TITakaaki Ito
Takaaki Ito
RARyo Ashida
Ryo Ashida
KUKatsuhiko Uesaka
Katsuhiko Uesaka